
Ticket prices go up Wednesday at midnight PST. Lock in your rate before then → syntheticbiologysummit.com/?… #SynBioBeta2027

The room where bio partnerships get made. F500 BD, VCs, and 2,000 founders — all in San Jose, May 3–6. syntheticbiologysummit.com/

Ticket prices go up Wednesday at midnight PST. Lock in your rate before then → syntheticbiologysummit.com/?… #SynBioBeta2027

Anyone want to see a Space Bio panel at SynBioBeta 2027?
What bio do people want in space ? Feel like there are a bunch of new biotech startups to make now @shelbynewsad @agupta @AdamDraper

SRTD Biotech just closed a €31.5M seed round, one of the largest biotech seeds in Europe. Oversubscribed and led by Mérieux Equity Partners, with @NRW.BANK and @Boehringer Ingelheim Venture Fund co-leading. @Lilly Ventures, @HTGF and @Anobis Asset joined too. What SRTD is building: • Programmable mRNA that switches on only in diseased cells • Regulatory RNA domains with AND / OR logic across marker combinations • A first focus on cancer cell killing, with other areas to follow Two big pharma venture arms backing a seed-stage company at this size is kind of wild. Their 2024 seed was a seven-figure round, so this is more than 3x that. The SynBio + AI angle is the part we like most. SRTD designs those regulatory RNA domains with in-house conditional diffusion models. Congrats to Heinz Köppl on stepping in as CTO, and to the whole SRTD team. Heinz is back at SynBioBeta this May. May 3-6, San Jose

Feed a chicken 900 calories and you get about 100 back. Bruce Friedrich of The Good Food Institute on why alternative protein is an efficiency argument, not a dietary one. #SynBioBeta

Mining companies have spent decades getting better at extracting from rich ore. Liz Dennett is building the tools to get more out of what's left behind. Dennett is Founder and CEO of Endolith, a biological intelligence platform helping mining companies improve mineral recovery from existing resources. Before Endolith, Dennett was CTO at Cemvita, with earlier leadership roles at AWS, Wood Mackenzie, and Biota Technology. Come find Liz Dennett in San Jose, May 3-6th, at @SynBioBeta.

DNA manufacturing has long meant choosing between speed, scale, and quality. Joe Hedley is building a company betting that is a false choice. Hedley is CEO and Co-Founder of NunaBio, built around an integrated enzymatic DNA platform combining enzyme-based technologies with proprietary hardware, aimed at compact, automated DNA production. NunaBio closed a £6.5M round led by Northstar Ventures to scale the platform. "This investment marks an important step in scaling a fundamentally new approach to DNA manufacturing." - Joe Hedley Come find Joe Hedley in San Jose, May 3-6th, at @SynBioBeta.

It was great visiting with @jrkelly and @Swamaway at @Ginkgo while I was in town for the Decode Bio Summit. Ginkgo is going big at SynBioBeta 2027, and we can't wait to share what's coming when we announce it. In the meantime, Ginkgo Cloud Labs just shared some incredible news this morning: • Researchers from @AnthropicAI (Yoon et al.) used AI agents to survey 1.9 billion protein clusters and flagged a family of array-associated reverse transcriptases (ARTs) next to CRISPR-like repeat arrays • The Ginkgo team wrapped Claude Opus 5 in a harness, gave it the preprint plus a catalog of validated Cloud Lab workflows, and had it design the wet-lab experiments • 13 days from experimental design to first evidence of biochemical activity • About $14,000 in cloud lab services • 2 of 4 enzymes tested (SA1 and LY01) showed self-primed reverse transcription across repeat-spacer junctions of their own array RNAs • Mutating the catalytic YxDD motif, or deleting the N-terminal domain, abolished activity It all ran on Nebula, Ginkgo's autonomous lab in Boston, as standardized workflows: cell-free protein synthesis, in vitro transcription, capillary electrophoresis, a HiBiT luminescence assay and qPCR. Humans stayed in the loop, reviewing designs and adding the HiBiT readout when the first assay lacked sensitivity. The team's takeaway: AI models plus robotic cloud labs should let researchers test hypotheses faster and cheaper than manual methods, and low-cost cloud lab work could open frontier experimental bioscience to far more people. Congratulations to @Swamaway, @mnapolitano89, Stephen McColm, Bradley Barber, Paula Ortuno, Izabela Carr and @jrkelly, and to everyone across Ginkgo Bioworks, including Ginkgo Cloud Labs, Ginkgo Automation, Ginkgo Reagents and the Nebula team. Congrats also to the @AnthropicAI researchers whose preprint started it. Can't wait to welcome the Ginkgo Bioworks team back for SynBioBeta 2027! #SynBioBeta #TechBio #CloudLab #AIforBiology

88% of product dollars in industrial biotech come from products that have been on the market twenty years. From BioAtlas, the 700-product open-source map built by Hawkwood Biotech and Genoa Ventures. #SynBioBeta

Nature Biotechnology just published a Focus on Climate Biotech, and it makes a clear case that these tools are coming of age. The issue covers low-methane rice, cellular agriculture, genetic control of mosquito-borne disease, and what fermentation can and can't replace in chemicals. It also includes a Comment on one of agriculture's biggest emissions sources: nitrogen fertilizer. "The next frontier in nitrogen fixation" argues that engineered nitrogen-fixing bacteria could be a sustainable alternative to chemical fertilizer, with a focus on rethinking how nitrogen biofertilizers are developed for cereal crops. • The focus issue: nature.com/collections/efbii… • The Comment: nature.com/articles/s41587-0… Congrats to @ScienceSchnabel, Timothy Haskett, @marcelobbatista, @samaddars, Hayley Knights, Valentina Infante, Jean-Michel Ané, Emanuel Maltempi de Souza, Ray Dixon and Philip Poole at @SwitchBioworks, @UniofOxford, @UWMadison, @JohnInnesCentre and @UFPR. Thank you to Kathryn Aschheim and the team at @NatureBiotech for pulling this issue together.

Congratulations to @Thomas G. Schmidt, @Per Falholt, @José Arnau, @Thorvald Ullum, @Barbara Taudorf Andersen, @Mathilde Pinon and the whole team at @21st.BIO on filing an EU Novel Food application for BLG Essential+, their precision-fermented beta-lactoglobulin, the main protein in whey. It was approved for sale in the US in October 2025, and per 21st.BIO it has 45% more leucine than commercially available whey protein isolate. The details worth knowing: • Made with Aspergillus oryzae, the fungus behind soy sauce and miso • Platform developed over decades at @Novonesis, then advanced by 21st.BIO • A 2025 peer-reviewed study calls the strain lineage the first mycotoxin-free A. oryzae lineage for industrial novel protein production • The ask: a fast-track EU pathway for well-characterized, nature-identical proteins from hosts with a demonstrated record of safe use Their case is that Europe has the science, the companies and the fermentation heritage (@Novonesis, Danish and EU research) but still needs a home market so the production plants get built in Europe. Whey supply is constrained, and BLG is a great fit for older adults, people on weight-loss medication who want to keep muscle, and anyone who needs compact nutrition. Yes, including Mars. I spent years at NASA on engineering biology for space, so I'm biased. Per spoke at SynBioBeta 2026, and we're building out food and ingredient innovation for SynBioBeta 2027, May 3-6 in San Jose. @Riccardo LoCascio and the Novonesis team, you'd be a great fit too. Hope to see you all there.

Watching a single chemical reaction happen, atom by atom, used to be the stuff of thought experiments. Jennifer Dionne's lab does it as a matter of course. Dionne is a Professor of Materials Science and Engineering at @stanford, deputy director of Q-NEXT, and a Chan Zuckerberg Biohub Investigator. Dionne co-founded Pumpkinseed, building quantum sensors for studying the immune system. Dionne's honors include a Presidential Early Career Award, the NSF Alan T. Waterman Award, and a Sloan Research Fellowship. Catch Dionne at "Biology's Missing Data Layer," at @SynBioBeta 2027. Come find Jennifer Dionne in San Jose, May 3-6th.

Running a weekly seminar that reaches more than 3,000 scientists worldwide is not a side project for Tae Seok Moon (@Moon_Synth_Bio). It's part of how Moon thinks science should work. Moon is a Full Professor at the J. Craig Venter Institute, director of an NSF Global Center, and founder of Moonshot Bio. Moon's 34 funded projects have secured $45.8M since 2012, resulting in 116 publications and 12 patents. Moon's SynBYSS seminar series has drawn 599 speakers to date, including a Nobel Laureate and 33 National Academy members. Come find Tae Seok Moon in San Jose, May 3-6th, at @SynBioBeta.

Nicole Richards of Allonnia asked her investors where to deploy first. They said they did not want to be first. "There are the people that will give you money, and the people that will help you go faster." #SynBioBeta

Biology hides its best cancer targets in the splicing. "One of the biggest bottlenecks is no longer just how to build the drug, it's where to point it." @envisagenics and @Boehringer Ingelheim, a match made in the room. Visit the @SynBioBeta website to read the full article. synbiobeta.com/read/the-drug… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬 syntheticbiologysummit.com/?…

Week 47
🔥 Week 47! 37 Bay Area Bio-economy events, Nov 16–22 🔥 David Baker gives two C. H. Li Memorial Lectures at @UCBerkeley. Randy Schekman with MCBcDNA. @GladstoneInst awards the Ogawa-Yamanaka Stem Cell Prize to Jun Takahashi. @biohub, @AnthropicAI and @nvidia on ESMFold2. All free. 🔗docs.google.com/spreadsheets… 🔗 The sheet has two tabs. 📅 By Day runs in calendar order, so you can plan your week. 🗂️ By Topic groups every event by field, so you can jump straight to yours. 𝗕𝗬 𝗧𝗢𝗣𝗜𝗖 🧬 9: Genomics, Proteins & Omics 🤖 7: AI & Computation 🌱 6: Industrial & Environmental Bio 🔬 4: Tools, Automation & Lab Ops 🧠 4: Neuro & BCI 💊 2: Drug Discovery & Trials 🏥 2: Clinical & Care Delivery 💰 2: Capital & Dealmaking 🎓 1: Career & Training 𝗕𝗬 𝗙𝗢𝗥𝗠𝗔𝗧 21: Seminar & Talk 11: Webinar 3: Conference & Summit 2: Networking & Social 𝗕𝗬 𝗟𝗢𝗖𝗔𝗧𝗜𝗢𝗡 13: Virtual 9: Berkeley 8: San Francisco 4: Stanford 2: South San Francisco 1: San Carlos 𝗕𝗬 𝗗𝗔𝗬 5: Monday, Nov 16 7: Tuesday, Nov 17 7: Wednesday, Nov 18 12: Thursday, Nov 19 5: Friday, Nov 20 1: Saturday, Nov 21 Thanks to the hosts: MBC BioLabs Berkeley Gateway Accelerator @GladstoneInst @biohub @OpenAI @LaunchBio @elucidatacorp @PythiaBio Rellia Health @BakerInstitute @RiceUniversity MCBcDNA @frontiertower @NeuroTechX @CALifeSciences @QBI_UCSF @genentech @teqfocus

Getting a synthetic biology breakthrough out of the lab is one problem. Getting a customer to actually buy it is another. Joshua Geilhufe has spent a career in the gap between the two. Geilhufe is an independent consultant at 838 Advisory, specializing in commercial strategy for platform biotechnologies in agriculture, industrials, and climate. Past roles include product development partnerships at Zymergen and Ginkgo Bioworks, and carbon capture research at Codexis. Techno-economic models Geilhufe built for microbial carbon capture secured funding and validation partnerships with Shell Canada and Holcim's Lafarge division. Come find Joshua Geilhufe in San Jose, May 3-6th, at @SynBioBeta.